Ligand Pharmaceuticals (LGND) Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Do analysts prefer LGND or ADMA?

Ligand Pharmaceuticals currently has a consensus target price of $147.17, indicating a potential upside of 14.51%. ADMA Biologics has a consensus target price of $27.67, indicating a potential upside of 54.37%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Which has more volatility & risk, LGND or ADMA?

Ligand Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Does the media favor LGND or ADMA?

In the previous week, Ligand Pharmaceuticals had 12 more articles in the media than ADMA Biologics. MarketBeat recorded 15 mentions for Ligand Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.31 beat Ligand Pharmaceuticals' score of 0.78 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better valuation and earnings, LGND or ADMA?

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$167.13M	14.83	-$4.03M	-$7.12	-18.05
ADMA Biologics	$426.45M	10.03	$197.67M	$0.85	21.08

Do insiders and institutionals hold more shares of LGND or ADMA?

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is LGND or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to Ligand Pharmaceuticals' net margin of -73.07%. ADMA Biologics' return on equity of 47.16% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	-73.07%	-7.83%	-6.92%
ADMA Biologics	45.01%	47.16%	30.51%

Summary

ADMA Biologics beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks.